Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Nov 24;22(7):1687–1698. doi: 10.1158/1078-0432.CCR-14-3378

Figure 5. TH-302 and sorafenib have synergistic activity in vivo.

Figure 5

A. Survival curves of NSG mice (N=5/group) transplanted with FLT/3ITD MOLM-13-LUC-GFP cells and treated with TH-302, sorafenib, or a combination starting on day 3 after cell injection. B. Quantification of tumor burden from bioluminescence images (BLI) on day 6 and 18 after cell transplantation. C. Optical imaging of mice transplanted with MOLM-13 cells and treated with vehicle, TH-302, sorafenib or the combination of TH-302 and sorafenib and performed on days 6, 18 and 26 after transplantation. X denotes mice that died.* P<0.05; ** P<0.01; *** P<0.001.